BE: study populations [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2007-11-22 14:44  – Posting: # 1326
Views: 5,731

Dear Jaime!

» If the drug is subjected to polymorphism, a BE study should be performed
» in geno-/phenotyped subjects, if:
» - a parallel design is used (e.g., for drugs with a long half-life);
» groups should be stratified for the respective geno-/phenotype.
» Example: if 20% of the population are slow/poor metabolisers and 80%
» fast/extensive ones, both groups (treated with either test or reference)
» should consist of the same percentage of SMs/FMs. Otherwise it would be
» impossible to calculate the treatment effect properly.

Just a few comments. IMHO it's no good idea to stratify groups for the phenotype, because drop-outs will change the SM (slow metabolizers) / FM (fast metabolizers)-ratio in such a way, that the treatment effect (which is based on group's means) will be biased.
Expanding your example:
Parallel design (2 groups of 30 subjects each; 24 FM (80%) and 6 SM (20%) in each group), responses (FM = 1, SM = 10)
Complete data set: GMT 1.58, GMR 1.58, GMR 100%
1 Drop out (Reference group, SM): GMT 1.58, GMR 1.49, GMR 1.07%
1 Drop out (Reference group, FM): GMT 1.58, GMR 1.61, GMR 0.98%

Therefore IMHO mixed groups should be avoided; only FM should be studied instead.
If stratified groups are to be used (i.e., due to a regulatory requirement), I would suggest laying down a procedure in the SAP excluding a subject of the same phenotype of the repective other group in a predefined blinded manner in order to keep the SM/FM ratio balanced. However, such a method is suboptimal.

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
20,635 posts in 4,324 threads, 1,434 registered users;
online 20 (1 registered, 19 guests [including 10 identified bots]).
Forum time: 23:14 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz